Clinical Experience of Patients with Ductal Carcinoma In Situ of the Breast Treated with Breast-Conserving Surgery plus Radiotherapy: A Preliminary Report.
- Author:
Ji Young JANG
1
;
Mi Ryeong RYU
;
Sung Whan KIM
;
Chul Seung KAY
;
Yeon Sil KIM
;
Yoon Kyeong OH
;
Hyung Chul KWON
;
Sei Chul YOON
;
Woo Chan PARK
;
Byung Joo SONG
;
Se Jeong OH
;
Sang Seol JUNG
;
Jong Man WON
;
Seung Nam KIM
;
Su Mi CHUNG
Author Information
1. Department of Radiation Oncology, Chosun University Hospital, Gwangju, Korea.
- Publication Type:Original Article
- Keywords:
Ductal carcinoma in situ;
Breast-conserving surgery;
Radiotherapy
- MeSH:
Breast Neoplasms;
Breast*;
Carcinoma, Ductal*;
Carcinoma, Intraductal, Noninfiltrating*;
Follow-Up Studies;
Humans;
Mastectomy;
Mastectomy, Segmental*;
Radiotherapy*;
Recurrence;
Survival Rate
- From:Cancer Research and Treatment
2005;37(6):344-348
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Breast-conserving therapy (BCT) is a practical alternative to mastectomy for treating ductal carcinoma in situ (DCIS). We reviewed our experience for treating patients with DCIS of the breast to evaluate the outcome after performing breast-conserving surgery plus radiotherapy (BCS-RT). MATERIALS AND METHODS: Between January 1983 and December 2002, 25 patients with clinically or mammographically detected DCIS were treated by BCS-RT. One patient was diagnosed with bilateral DCIS. Thirteen cases (50%) had symptomatic lesions at presentation. All 26 cases of 25 patients underwent BCS such as lumpectomy, partial mastectomy or quadrantectomy. All of them received whole breast irradiation to a median dose of 50.4 Gy. Twenty-four cases (92.3%) received a boost to the tumor bed for a median total dose of 59.4 Gy. The median follow up period was 67 months (range: 38 to 149 months). RESULTS: Two cases (7.7%) experienced ipsilateral breast tumor recurrence (IBTR) after BCS-RT. The histology results at the time of IBTR showed invasive ductal carcinoma (IDC), and the median time to IBTR was 25.5 months. On the univariate analysis, there were no significant factors associated with IBTR in the DCIS patients. The three-year local recurrence free survival rate was 96.0% and the overall survival rate was 96.3%. CONCLUSION: After the treatment for DCIS, the IBTR rate in our study was similar to other previous studies. Considering that we included patients who had many symptomatic lesions, close or positive margins and less that complete early data, our result is comparable to the previous studies. We could not find the prognostic significant factors associated with IBTR after BCS-RT. A longer follow up period with more patients would be required to evaluate the role of any predictive factors and to confirm these short-term results.
